MAY 1 3 2002 Docket No. DIE01-NP002

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dietzschold

Group Art Unit: 1635

Examiner: Tara Washington

Serial No.:

09/924,112

Filed:

August 7, 2001

THREE MONTHS OF FILING OR

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN

BEFORE MAILING OF FIRST OFFICE **ACTION (37 CFR 1.97(b))**

Title: "Rhabdovirus-based Vectors to

Express High Levels of Functional:

Human Antibodies"

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Dear Sir:

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Respectfully submitted,

Date: May 7, 2002

Janet B. Smith, Ph.D.

Patent Agent

Registration No: 45,461

Thomas Jefferson University

1020 Walnut Street – 6th Floor

Phone No: (215) 503-2386

Philadelphia, PA 19103-2793

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: May 7, 2002

Docket No.: DIRECEIVED

ATES PATENT AND TRADEMARK OFFICE 3 2002 IN THE UNITED S

In re Application of:

TECH CENTER 1600/2900

Group Art Unit: 1635

Dietzschold

Examiner: Tara Washington

Serial No.:

09/924,112

INFORMATION

Filed:

August 7, 2001

DISCLOSURE **STATEMENT**

Title:

"Rhabdovirus-based Vectors:

to Express High Levels of

Functional Human

Antibodies"

Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

List Of Sections Forming Part Of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

:

- **Preliminary Statements**
- 2. Form PTO - 1449 (Modified)
- Copies of Listed Information Items Accompanying This Statement 3.
- Identification of Person(s) Making This Information Disclosure Statement 4.

Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

05/10/2002 HNOOR1

00000115 500491 09924112

01 FC:126

180.00 CH



RECEIVED

MAY 1 3 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to: Box Issue Fee, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

Janyce Lingo

RECEIVED

U.S. Department of Commerce Patent and Trademark Office Form PTO - 1449 Docket No: **DIE01-NP002** (Modified) Serial No.: 09/924, 112 DIETZCHOLD, BALCHCENTER 1600/2900 Applicant: **Information Disclosure** Filing Date: August 7, 2001 0 7 2002 Statement by Approximation (use several Sheets if necessar Statement by Applicant Art No. 1635 Examiner Tara Washington U.S DOCUMENTS Exmr Issue Sub-Filing Date Patent Number Initial Date Patentee Class Class If Appropriate FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Exmr Document Number Publn Sub-Translation? Initial Date* Country or Patent Office Class Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**) Whitelam, G., Cockburn, W., & Owen, M. "Antibody Production in Transgenic Plants." AA Biochemical Society Transactions 22: 940-949, 1994. Habel, K. "Isogeneic Versus Allogeneic Antiserum in the Prophylaxis of Experimental Rabies." AB Bulletin of the World Health Organization 38: 383-387, 1968. Schnell, M., Mebatsion, T., & Conzelmann, K. "Infectious Rabies Viruses From Cloned cDNA." AC The EMBO Journal 13 (18): 4195-4203, 1994. Arakawa, F., Haruno, M., Kuroki, M., Kanda, H., Watanabe, T., Misumi, Y., & Matsuoka, Y. AD "Construction and Expression of Two Mouse-human Chimeric Antibodies with High Specificity and Affinity for Carcinoembryonic Antigen." Hybridoma 12 (4): 365-379, 1993. AE Ueki, Y., Goldfarb, I., Harindranath, N., Gore, M., Koprowski, H., Notkins, A., & Casali, P. "Clonal analysis of a Human Antibody Response." The Journal of Experimental Medicine 171: 19-34, 1990. Dietzschold, B., Gore, M., Casali, P., Ueki, Y., Rupprecht, C., Notkins, A., & Koprowski, H. AF "Biological characterization of Human Monoclonal Antibodies to Rabies Virus." Journal of Virology 64 (6): 3087-3090, 1990. Beidler, C., Ludwig, J., Cardenas, J., Phelps, J., Papworth, C., Melcher, E., Sierzega, M., Myers, AG L., Unger, B., Fisher, M., David, G., & Johnson, M. "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen." Journal of Immunology 141 (11) 4053-4060, 1988. Champion, J., Kean, R., Rupprecht, C., Notkins, A., Koprowski, H., Dietzschold, B., & Hooper, D. AH "The Development of Monoclonal Human Rabies Virus-neutralizing Antibodies as a Substitute for Pooled Human Immune Globulin in the Prophylactic Treatment of Rabies Virus Exposure." Journal of Immunology 235: 81-90, 2000. Buchholz, U., Finke, S., & Conzelmann, K. "Generation of Bovine Respiratory Syncytial Virus ΑI (BRSV) from cDNA: BRSV NS2 is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter." Journal of Virology 73 (1): 251-259, 1999.

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449)

Date Considered

Examiner

^{*} Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

^{**} The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.

Section 2. Form PTO - 14-9 (Continued)

RECEIVED

MERITER 1800/2900

Form P (Modif	ied) - Pa 	tent and Trademark Office formation Disclosure atement by Applicant several Sheets if necessar	e way fi 7	2002	Docket No: Serial No.: Applicant: Filing Date: Art No. Examiner	1033	NP002 112 SCHOL I 7, 2001 Vashington	CH CENTER 16
			U.S. PA	ATENT DO	CUMENTS			
Exmr Initial		Patent Number	Issue Date	Patentee		Class	Sub- Class	Filing Date If Appropriate
	<u> </u>	EODELCN DATENT	OD DUD	I ICHED E	ODELGNIDATI		CARTON	
Exmr Initial		Document Number	Publn Date*		or Patent Office		Sub- Class	Translation? Yes No
	<u> </u>	OTHER DOCUMENT	S (Includ	ling Author	Title Date P	loop of Dubl	ication**)	
	AJ AK	OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**) Morimoto, K., Hooper, D., Carbaugh, H., Fu, Z., Koprowski, H., & Dietzschold, B. "Rabies Virus Quasispecies: Implications for Pathogenesis." <i>Proceedings of the National Academy of Science, USA 95</i> : 3152-3156, 1998. Schnell, M., Foley, H., Siler, C., McGettigan, J., Dietzschold, B., & Pomerantz, R. "Recombinant						
	AL	Rabies Virus as Potential Live-viral Vaccines for HIV-1." Proceedings of the National Academy of Science, USA 97 (7): 3544-3549, 2000. Steele, J. "Rabies in the Americas and Remarks on Global Aspects." Reviews of Infectious						
	AM	Diseases 10 (4): S585-S597, 1988. Liang, M., Guttieri, M., Lundkvist, A., & Schmaljohn, C. "Baculovirus Expression of a Human G2-Specific, Neutralizing IgG Monoclonal Antibody to Puumala Virus." Virology 235: 252-260, 1977.						
	AN AO	Finke, S., & Conzelmann, K. "Virus Promoters Determine Interference by Defective RNAs: Selective Amplification of Mini-RNA Vectors and Rescue from cDNA by a 3' Copy-back Ambisense Rabies Virus." Journal of Virology 73 (5): 3818-3825, 1999.						
	AP	Ovens, R., & Young, R. "The Genetic Engineering of Monoclonal Antibodies." Journal of Immunological Methods 168: 149-165, 1994. Dietzschold, B., Morimoto, K., Hooper, D., Smith, J., Rupprecht, C., & Koprowski, H. "Genotypic & Phenotypic Diversity of Rabies Virus Variants Involved in Human Rabies: Implications for Postexposure Prophylaxis." Journal of HumanVirology 3 (1): 50-57, 2000.						
	AQ	Wilde, H., Choomkasien, P., Hemachudha, T., Supich, C., & Chutivongse, S. "Failure of Rabies Postexposure Treatment in Thailand." <i>Vaccine</i> 7: 49-52, 1989.						
Examine	er			Date	e Considered	1		

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449)

Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.